{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:44:30Z","timestamp":1792799070080,"version":"4.5.0"},"reference-count":35,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Stanford Innovative Medicines Accelerator","award":["no award\/grant number"],"award-info":[{"award-number":["no award\/grant number"]}]},{"name":"Stanford Vera Moulton Wall Center for Pulmonary Vascular Disease","award":["5R01HL172449-02"],"award-info":[{"award-number":["5R01HL172449-02"]}]},{"name":"Stanford Vera Moulton Wall Center for Pulmonary Vascular Disease","award":["R01HL134776"],"award-info":[{"award-number":["R01HL134776"]}]},{"name":"Stanford Vera Moulton Wall Center for Pulmonary Vascular Disease","award":["R01HL139664"],"award-info":[{"award-number":["R01HL139664"]}]},{"name":"Stanford Vera Moulton Wall Center for Pulmonary Vascular Disease","award":["R01HL160018"],"award-info":[{"award-number":["R01HL160018"]}]},{"name":"Stanford Vera Moulton Wall Center for Pulmonary Vascular Disease","award":["R01HL59886"],"award-info":[{"award-number":["R01HL59886"]}]},{"name":"Stanford Medicine Catalyst","award":["no award\/grant number"],"award-info":[{"award-number":["no award\/grant number"]}],"id":[{"id":"https:\/\/ror.org\/03mtd9a03","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2025,4,22]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pulmonary hypertension (PH) is a progressive cardiopulmonary condition associated with increased morbidity and mortality. The extracellular matrix component hyaluronan (HA) is linked to vascular remodelling and interstitial fibrosis in PH. We hypothesised that inhibition of HA synthesis with hymecromone could serve as a reverse-remodelling therapy in PH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a proof-of-concept phase IIa randomised, double-blind, placebo-controlled study in adults with pulmonary arterial hypertension and PH associated with interstitial lung disease (PH-ILD). Patients were randomised to a 5:3 ratio and stratified by PH group to receive oral hymecromone or placebo two times per day over 24 weeks. The primary endpoint was change in pulmonary vascular resistance (PVR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We enrolled 16 patients with PH with a median age of 62.0 years. There were no treatment-related adverse events leading to hymecromone discontinuation. No statistically significant difference in PVR was observed at 24 weeks for the experimental group compared with the placebo group (mean difference 0.61 Wood unit, 95%\u2009CI \u22121.5 to 2.7). Five patients with PH-ILD treated with hymecromone demonstrated an unadjusted absolute mean increase in 6\u2009min walk distance of 66 m (SD 69.6) from baseline to 24 weeks and improvements in quality-of-life measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our exploratory analyses suggest that treatment with hymecromone could lead to improvements in clinically meaningful functional parameters in patients with PH-ILD. Further investigations in larger patient cohorts are warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05128929\">NCT05128929<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2024-222725","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T13:20:21Z","timestamp":1748784021000},"page":"632-640","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Randomised, placebo-controlled trial of oral hymecromone in adults with pulmonary hypertension"],"prefix":"10.1136","volume":"80","clinical-trial-number":[{"clinical-trial-number":"nct05128929","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-0122","authenticated-orcid":false,"given":"Kathryn","family":"Czepiel","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Population Health, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2638-2436","authenticated-orcid":false,"given":"Nadine","family":"Nagy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamera","family":"Panjalingam","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Pulmonary and Critical Care, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3298-5580","authenticated-orcid":false,"given":"Anissa","family":"Kalinowski","sequence":"additional","affiliation":[{"name":"Halo Biosciences Inc, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam R","family":"Frymoyer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Karmouty-Quintana","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3217-7655","authenticated-orcid":false,"given":"Bo","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Quantitative Sciences Unit, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-7959","authenticated-orcid":false,"given":"Haley","family":"Hedlin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Quantitative Sciences Unit, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6184-5192","authenticated-orcid":false,"given":"Gernot","family":"Kaber","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-2105","authenticated-orcid":false,"given":"Sylvie","family":"Dobrota Lai","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle I","family":"Rosser","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Disease and Geographic Medicine, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L","family":"Bollyky","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Disease and Geographic Medicine, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5532-8247","authenticated-orcid":false,"given":"Vinicio","family":"de Jesus Perez","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Pulmonary and Critical Care, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roham T","family":"Zamanian","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Pulmonary and Critical Care, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,1]]},"reference":[{"key":"2025081509100671000_80.9.632.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac237"},{"key":"2025081509100671000_80.9.632.2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-023-00486-7","article-title":"Pulmonary hypertension","volume":"10","author":"Mocumbi","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2025081509100671000_80.9.632.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.012"},{"key":"2025081509100671000_80.9.632.4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"2025081509100671000_80.9.632.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.847707"},{"key":"2025081509100671000_80.9.632.6","article-title":"Group 3 pulmonary hypertension: Challenges and opportunities","volume":"2020","author":"McGettrick","year":"2020","journal-title":"Glob Cardiol Sci Pract"},{"key":"2025081509100671000_80.9.632.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00279.x"},{"key":"2025081509100671000_80.9.632.8","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13947"},{"key":"2025081509100671000_80.9.632.9","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.90306.2008"},{"key":"2025081509100671000_80.9.632.10","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00159507"},{"key":"2025081509100671000_80.9.632.11","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00168.2015"},{"key":"2025081509100671000_80.9.632.12","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24183291","article-title":"Hyaluronic Acid-Decorated Liposomes as Innovative Targeted Delivery System for Lung Fibrotic Cells","volume":"24","author":"Pandolfi","year":"2019","journal-title":"Molecules"},{"key":"2025081509100671000_80.9.632.13","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.038711","article-title":"Adenosine and hyaluronan promote lung fibrosis and pulmonary hypertension in combined pulmonary fibrosis and emphysema","volume":"12","author":"Collum","year":"2019","journal-title":"Dis Model Mech"},{"key":"2025081509100671000_80.9.632.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.23409.x"},{"key":"2025081509100671000_80.9.632.15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.12.8191"},{"key":"2025081509100671000_80.9.632.16","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-014-0092-y"},{"key":"2025081509100671000_80.9.632.17","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3390\/toxins5101814","article-title":"Treatment with the hyaluronic acid synthesis inhibitor 4-methylumbelliferone suppresses SEB-induced lung inflammation","volume":"5","author":"McKallip","year":"2013","journal-title":"Toxins (Basel)"},{"key":"2025081509100671000_80.9.632.18","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.459"},{"key":"2025081509100671000_80.9.632.19","article-title":"Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives","volume":"2017","author":"Collum","year":"2017","journal-title":"Can Respir J"},{"key":"2025081509100671000_80.9.632.20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00123","article-title":"4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer","volume":"6","author":"Nagy","year":"2015","journal-title":"Front Immunol"},{"key":"2025081509100671000_80.9.632.21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI79271"},{"key":"2025081509100671000_80.9.632.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.37861"},{"key":"2025081509100671000_80.9.632.23","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157983","article-title":"Oral hymecromone decreases hyaluronan in human study participants","volume":"132","author":"Rosser","year":"2022","journal-title":"J Clin Invest"},{"key":"2025081509100671000_80.9.632.24","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"2025081509100671000_80.9.632.25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202208-1547OC"},{"key":"2025081509100671000_80.9.632.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2024.07.020"},{"key":"2025081509100671000_80.9.632.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2023.09.003"},{"key":"2025081509100671000_80.9.632.28","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s42255-019-0055-6","article-title":"4-Methylumbelliferone improves the thermogenic capacity of brown adipose tissue","volume":"1","author":"Grandoch","year":"2019","journal-title":"Nat Metab"},{"key":"2025081509100671000_80.9.632.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-83796-8","article-title":"Screening of metabolic modulators identifies new strategies to target metabolic reprogramming in melanoma","volume":"11","author":"Abildgaard","year":"2021","journal-title":"Sci Rep"},{"key":"2025081509100671000_80.9.632.30","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600830128"},{"key":"2025081509100671000_80.9.632.31","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12815"},{"key":"2025081509100671000_80.9.632.32","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510140103"},{"key":"2025081509100671000_80.9.632.33","doi-asserted-by":"publisher","DOI":"10.4103\/2045-8932.109933"},{"key":"2025081509100671000_80.9.632.34","doi-asserted-by":"crossref","first-page":"2045894020941491","DOI":"10.1177\/2045894020941491","article-title":"Clinical trial design in phase 2 and 3 trials for pulmonary hypertension","volume":"10","author":"Nikkho","year":"2020","journal-title":"Pulm Circ"},{"key":"2025081509100671000_80.9.632.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008470"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2024-222725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T13:03:33Z","timestamp":1759928613000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2024-222725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,8,15]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/thorax-2024-222725"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2024-222725","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}